Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:
RDY), announced its partnership with Biotechnology Industry
Research Assistance Council (BIRAC), Department of Biotechnology
(DBT), Government of India, for advisory support on clinical trials
of Sputnik V vaccine in India.
The partnership will allow Dr. Reddy’s to identify and use some
of BIRAC’s clinical trial centres for the vaccine, which are funded
under the National Biopharma Mission (NBM), implemented by Project
Management Unit-NBM at BIRAC. Further, the Company will have access
to Good Clinical Laboratory Practice (GCLP) labs to conduct
immunogenicity assay testing of the vaccine.
Satish Reddy, Chairman, Dr. Reddy’s Laboratories said, “We are
pleased with the collaboration with BIRAC as an advisory partner
for clinical trials of the Sputnik V vaccine in India. We look
forward to working with them to accelerate our efforts in bringing
the vaccine to India.”
Commenting on the collaboration with Dr. Reddy’s, Dr Renu
Swarup, Secretary, DBT and Chairperson, BIRAC said, "The government
is committed to fast track clinical development of COVID vaccine
candidates and provide facilitation to accelerate market readiness
of a suitable vaccine. We at DBT look forward to this partnership
with Dr. Reddy’s for this Indo Russian Collaboration for Vaccine
Development."
Earlier this month, Dr. Reddy’s and Russia Direct Investment
Fund (RDIF) received approval from the Drugs Controller General of
India (DCGI) to conduct an adaptive phase 2/3 human clinical trial
for Sputnik V vaccine in India.
On August 11, 2020, the Sputnik V vaccine developed by the
Gamaleya National Research Institute of Epidemiology and
Microbiology was registered by the Ministry of Health of Russia and
became the World’s first registered vaccine against COVID-19 based
on the human adenoviral vector platform.
About Dr. Reddy’s: Dr. Reddy's Laboratories Ltd. (BSE:
500124, NSE: DRREDDY, NYSE: RDY, hereinafter “Dr. Reddy's”) is an
integrated pharmaceutical company, committed to providing
affordable and innovative medicines for healthier lives. Through
its three businesses - Pharmaceutical Services & Active
Ingredients, Global Generics and Proprietary Products – Dr. Reddy's
offers a portfolio of products and services including APIs, custom
pharmaceutical services, generics, biosimilars and differentiated
formulations. Our major therapeutic areas of focus are
gastrointestinal, cardiovascular, diabetology, oncology, pain
management and dermatology. Dr. Reddy's operates in markets across
the globe. Our major markets include – USA, India, Russia & CIS
countries, and Europe. For more information, log on to:
www.drreddys.com.
About RDIF: Russian Direct Investment Fund (RDIF) is
Russia's sovereign wealth fund established in 2011 to make equity
co-investments, primarily in Russia, alongside reputable
international financial and strategic investors. RDIF acts as a
catalyst for direct investment in the Russian economy. RDIF’s
management company is based in Moscow. Currently, RDIF has
experience of the successful joint implementation of more than 80
projects with foreign partners totaling more than RUB1.9 tn and
covering 95% of the regions of the Russian Federation. RDIF
portfolio companies employ more than 800,000 people and generate
revenues which equate to more than 6% of Russia’s GDP. RDIF has
established joint strategic partnerships with leading international
co-investors from more than 18 countries that total more than $40
bn. Further information can be found at www.rdif.ru
About DBT: The Department of Biotechnology (DBT), under
the Ministry of Science & Technology, promotes the use and
application of biotechnology in the areas of agriculture,
healthcare, animal sciences, environment and industry. It is
focused on attaining new heights in biotechnology research, shaping
biotechnology into a premier precision tool of the future for
creation of wealth and ensuring social justice – especially for the
welfare of the poor. www.dbtindia.gov.in
About BIRAC: Biotechnology Industry Research Assistance
Council (BIRAC) is a not-for-profit Section 8, Schedule B, Public
Sector Enterprise, set up by Department of Biotechnology (DBT),
Government of India as an Interface Agency to strengthen and
empower the emerging Biotech enterprise to undertake strategic
research and innovation, addressing nationally relevant product
development needs.
Disclaimer: This press release may include statements of
future expectations and other forward-looking statements that are
based on the management’s current views and assumptions and involve
known or unknown risks and uncertainties that could cause actual
results, performance or events to differ materially from those
expressed or implied in such statements. In addition to statements
which are forward-looking by reason of context, the words "may",
"will", "should", "expects", "plans", "intends", "anticipates",
"believes", "estimates", "predicts", "potential", or "continue" and
similar expressions identify forward-looking statements. Actual
results, performance or events may differ materially from those in
such statements due to without limitation, (i) general economic
conditions such as performance of financial markets, credit
defaults, currency exchange rates, interest rates, persistency
levels and frequency / severity of insured loss events, (ii)
mortality and morbidity levels and trends, (iii) changing levels of
competition and general competitive factors, (iv) changes in laws
and regulations and in the policies of central banks and/or
governments, (v) the impact of acquisitions or reorganization,
including related integration issues, and (vi) the susceptibility of our industry
and the markets addressed by our, and our customers’, products and
services to economic downturns as a result of natural disasters,
epidemics, pandemics or other widespread illness, including
coronavirus (or COVID-19), and (vii) other risks and uncertainties
identified in our public filings with the Securities and Exchange
Commission, including those listed under the "Risk Factors" and
"Forward-Looking Statements" sections of our Annual Report on Form
20-F for the year ended March 31, 2020. The company assumes no
obligation to update any information contained herein.”
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201028006327/en/
INVESTOR RELATIONS AMIT AGARWAL amita@drreddys.com (PH: +91-40-49002135)
MEDIA RELATIONS APARNA TEKURI aparnatekuri@drreddys.com (PH:
+91-40-49002446)
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Apr 2023 to Apr 2024